{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:35:16Z","timestamp":1790487316894,"version":"4.1.0"},"reference-count":70,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Cytomegalovirus (CMV) is the most common cause of congenital infection and non-genetic sensorineural hearing loss in childhood. Up to 2% of neonates, with the highest percentages found in developing countries, are congenitally infected with CMV. At birth, most of these infants are asymptomatic. However, approximately 10% have signs and symptoms of the disease, and 40\u201360% of symptomatic neonates will later develop permanent neurologic sequelae. To reduce congenital CMV (cCMV) infection, a vaccine able to prevent primary infection is essential. In this narrative review, actual ongoing research about the development of a CMV vaccine is discussed. The progressive increase in knowledge on the ways in which the host\u2019s immune system and CMV relate has made it possible to clarify that the development of a vaccine that is certainly capable of reducing the risk of cCMV infection, and preventing both primary and nonprimary infections is extremely difficult. Many of the ways in which the virus evades the immune system and causes cCMV infection are not yet fully understood, especially in cases of nonprimary infection. Moreover, the schedule that should be recommended and that subjects must be vaccinated to obtain the greatest effect have not been precisely defined. Further studies are needed before the problem of cCMV infection and its related challenges can be totally solved.<\/jats:p>","DOI":"10.3390\/vaccines9050523","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T23:34:46Z","timestamp":1621380886000},"page":"523","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prevention of Congenital Cytomegalovirus Infection with Vaccines: State of the Art"],"prefix":"10.3390","volume":"9","author":[{"given":"Susanna","family":"Esposito","sequence":"first","affiliation":[{"name":"Pediatric Clinic, Pietro Barilla Children\u2019s Hospital, University of Parma, Via Gramsci 14, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Chiopris","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Pietro Barilla Children\u2019s Hospital, University of Parma, Via Gramsci 14, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Messina","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Pietro Barilla Children\u2019s Hospital, University of Parma, Via Gramsci 14, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"D\u2019Alvano","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Pietro Barilla Children\u2019s Hospital, University of Parma, Via Gramsci 14, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serafina","family":"Perrone","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Neonatology Unit, Pietro Barilla Children\u2019s Hospital, University of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3468-5568","authenticated-orcid":false,"given":"Nicola","family":"Principi","sequence":"additional","affiliation":[{"name":"University degli Studi di Milano, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/1753495X14552719","article-title":"Congenital cytomegalovirus infection: Clinical presentation, epidemiology, diagnosis and prevention","volume":"7","author":"Hamilton","year":"2014","journal-title":"Obstet. Med."},{"key":"ref_2","unstructured":"Knipe, D.M., and Howley, P.M. (2013). Cytomegaloviruses. Fields Virology, Lippincott Williams & Wilkins. [6th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1093\/cid\/cit629","article-title":"Congenital Cytomegalovirus Infection: Clinical Outcome","volume":"57","author":"Boppana","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/bdra.23601","article-title":"Cytomegalovirus infection in pregnancy","volume":"109","author":"Davis","year":"2017","journal-title":"Birth Defects Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-0032-1333133","article-title":"Cytomegalovirus: Should We Screen Pregnant Women for Primary Infection?","volume":"30","author":"Anderson","year":"2013","journal-title":"Am. J. Perinatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1001\/jama.1986.03380140074025","article-title":"Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome","volume":"256","author":"Stagno","year":"1986","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1542\/peds.104.1.55","article-title":"Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus","volume":"104","author":"Boppana","year":"1999","journal-title":"Pediatrics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/00365549950163969","article-title":"Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature","volume":"31","author":"Ahlfors","year":"1999","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM199203053261003","article-title":"The Outcome of Congenital Cytomegalovirus Infection in Relation to Maternal Antibody Status","volume":"326","author":"Fowler","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Coppola, T., Mangold, J.F., Cantrell, S., and Permar, S.R. (2019). Impact of Maternal Immunity on Congenital Cytomegalovirus Birth Prevalence and Infant Outcomes: A Systematic Review. Vaccines, 7.","DOI":"10.3390\/vaccines7040129"},{"key":"ref_11","unstructured":"Stratton, K.R., Durch, J.S., and Lawrence, R.S. (2000). The National Academies Collection: Reports funded by National Institutes of Health. Vaccines for the 21st Century: A Tool for Decision Making, National Academies Press."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1093\/infdis\/jiz448","article-title":"Preventing Infection by Human Cytomegalovirus","volume":"221","author":"Plotkin","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41541-018-0074-4","article-title":"A new era in cytomegalovirus vaccinology: Considerations for rational design of next-generation vaccines to prevent congenital cytomegalovirus infection","volume":"3","author":"Nelson","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/tri.12629","article-title":"Cytomegalovirus post kidney transplantation: Prophylaxis versus pre-emptive therapy?","volume":"28","author":"Fehr","year":"2015","journal-title":"Transpl. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.trre.2016.04.001","article-title":"Management of cytomegalovirus infection in solid organ transplant recipients: SET\/GESITRA-SEIMC\/REIPI recommendations","volume":"30","author":"Aguado","year":"2016","journal-title":"Transplant. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1084\/jem.187.10.1681","article-title":"Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: The role of endogenous class I major histocompatibility complex and a viral class I homolog","volume":"187","author":"Leong","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJM198906293202605","article-title":"Severe Herpesvirus Infections in an Adolescent without Natural Killer Cells","volume":"320","author":"Biron","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ni1156","article-title":"Downregulation of natural killer cell\u2013activating ligand CD155 by human cytomegalovirus UL141","volume":"6","author":"Tomasec","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.4049\/jimmunol.164.9.4775","article-title":"Human Cytomegalovirus Strain-Dependent Changes in NK Cell Recognition of Infected Fibroblasts","volume":"164","author":"Cerboni","year":"2000","journal-title":"J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Forrest, C., Gomes, A., Reeves, M., and Male, V. (2020). NK Cell Memory to Cytomegalovirus: Implications for Vaccine Development. Vaccines, 8.","DOI":"10.3390\/vaccines8030394"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1128\/JVI.01818-08","article-title":"Major tegument protein pp65 of human cytomegalovirus is required for the incorporation of pUL69 and pUL97 into the virus particle and for viral growth in macrophages","volume":"83","author":"Chevillotte","year":"2009","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3390\/v1030760","article-title":"The Human Cytomegalovirus Major Immediate-Early Proteins as Antagonists of Intrinsic and Innate Antiviral Host Responses","volume":"1","author":"Paulus","year":"2009","journal-title":"Viruses"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/jmv.25225","article-title":"Human cytomegalovirus (HCMV)-specific T cell but not neutralizing or IgG binding antibody responses to glycoprotein complexes gB, gHgLgO, and pUL128L correlate with protection against high HCMV viral load reactivation in solid-organ transplant recipients","volume":"90","author":"Lilleri","year":"2018","journal-title":"J. Med. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/cid\/cix622","article-title":"Human Cytomegalo-virus-Specific Memory CD4+ T-Cell Response and Its Correlation with Virus Transmission to the Fetus in Pregnant Women with Primary Infection","volume":"65","author":"Fornara","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1128\/JVI.73.6.4806-4812.1999","article-title":"Quantitative Analysis of Latent Human Cytomegalovirus","volume":"73","author":"Slobedman","year":"1999","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3389\/fcimb.2020.00476","article-title":"Control of Immediate Early Gene Expression for Human Cytomegalovirus Reactivation","volume":"10","author":"Kamil","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fcimb.2020.00130","article-title":"Cytomegalovirus Latency and Reactivation: An Intricate Interplay with the Host Immune Response","volume":"10","author":"Forte","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Schleiss, M.R., and Diamond, D.J. (2020). Exciting Times for Cytomegalovirus (CMV) Vaccine Development: Navigating the Pathways toward the Goal of Protecting Infants against Congenital CMV Infection. Vaccines, 8.","DOI":"10.3390\/vaccines8030526"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1128\/JVI.01910-07","article-title":"Characterization of the human cytomegalovirus gH\/gL\/UL128-131 complex that mediates entry into epithelial and endothelial cells","volume":"82","author":"Ryckman","year":"2008","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17965","DOI":"10.1073\/pnas.1415310111","article-title":"Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies","volume":"111","author":"Kabanova","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1073\/pnas.1800177115","article-title":"HCMV glycoprotein B subunit vaccine efficacy mediated by nonneu-tralizing antibody effector functions","volume":"115","author":"Nelson","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(84)90930-9","article-title":"Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants","volume":"323","author":"Plotkin","year":"1984","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/infdis\/159.5.860","article-title":"Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge","volume":"159","author":"Plotkin","year":"1989","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/rmv.315","article-title":"A review of genetic differences between limited and extensively passaged human cytomegalovirus strains","volume":"11","author":"Prichard","year":"2001","journal-title":"Rev. Med. Virol."},{"key":"ref_35","unstructured":"Heineman, T., Schleiss, M., Bernstein, D., Fast, P., Spaete, R., and Kemble, G. (2002;, January 20\u201326). Preliminary safety results from a phase 1 study of four new live, recombinant HCMV Towne\/Toledo chimeric vaccines. Proceedings of the Abstracts of the 27th Herpes Simplex Virus Workshop, Cairns, Australia."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/infdis\/jiw365","article-title":"A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne\/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men","volume":"214","author":"Adler","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The history of MF59\u00ae adjuvant: A phoenix that arose from the ashes","volume":"12","author":"Ott","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/1469-0691.12449","article-title":"Cytomegalovirus vaccine: Phase II clinical trial results","volume":"20","author":"Rieder","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/infdis\/jir138","article-title":"Glycoprotein B Vaccine Is Capable of Boosting Both Antibody and CD4 T-Cell Responses to Cytomegalovirus in Chronically Infected Women","volume":"203","author":"Sabbaj","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems","volume":"10","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1016\/j.vaccine.2018.07.056","article-title":"Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response","volume":"36","author":"Cui","year":"2018","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"18153","DOI":"10.1073\/pnas.0509201102","article-title":"Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism","volume":"102","author":"Wang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e1921","DOI":"10.1002\/rmv.1921","article-title":"Maternal immune correlates of protection from human cytomegalovirus transmission to the fetus after primary infection in pregnancy","volume":"27","author":"Lilleri","year":"2017","journal-title":"Rev. Med. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1086\/314951","article-title":"A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne)","volume":"180","author":"Adler","year":"1999","journal-title":"J. Infect Dis."},{"key":"ref_47","unstructured":"U.S. National Library of Medicine (2021, February 20). ClinicalTrials gov. A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) (HELIOS), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01877655."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/blood-2016-07-729756","article-title":"MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults","volume":"129","author":"Longmate","year":"2017","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"306","DOI":"10.7326\/M19-2511","article-title":"Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial","volume":"172","author":"Aldoss","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/infdis\/jis107","article-title":"Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant","volume":"205","author":"Longmate","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1086\/588385","article-title":"Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects","volume":"197","author":"Wloch","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/vaccines1040398","article-title":"Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 Trial","volume":"1","author":"Smith","year":"2013","journal-title":"Vaccines"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Perotti, M., Marcandalli, J., Demurtas, D., Sallusto, F., and Perez, L. (2020). Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1009169"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Contreras, H., Wussow, F., Fern\u00e1ndez-Alarc\u00f3n, C., Bierle, C., Nguyen, J., Diamond, D.J., and Schleiss, M.R. (2019). MVA-vectored pentameric complex (PC) and gB vaccines improve pregnancy outcome after guinea pig CMV challenge, but only gB vaccine reduces vertical transmission. Vaccines, 7.","DOI":"10.3390\/vaccines7040182"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","article-title":"Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity","volume":"36","author":"John","year":"2018","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e00186-20","DOI":"10.1128\/JVI.00186-20","article-title":"Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization","volume":"94","author":"Nelson","year":"2020","journal-title":"J. Virol."},{"key":"ref_58","unstructured":"Moderna (2021, April 20). Moderna Announces Clinical Progress from its Industry-Leading mRNA Vaccine Franchise and Continues Investments to Accelerate Pipeline Development. Available online: https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-announces-clinical-progress-its-industry-leading-mrna."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Perotti, M., and Perez, L. (2019). Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV. Viruses, 12.","DOI":"10.3390\/v12010035"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.vaccine.2013.09.042","article-title":"Priorities for CMV vaccine development","volume":"32","author":"Krause","year":"2013","journal-title":"Vaccine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/rmv.659","article-title":"Cytomegalovirus seroconversion rates and risk factors: Implications for congenital CMV","volume":"20","author":"Hyde","year":"2010","journal-title":"Rev. Med. Virol."},{"key":"ref_62","unstructured":"Centers for Disease Control and Prevention (2021, February 20). Vaccines and Preventable Diseases. Administering HPV Vaccine. Dosage and Schedule, Available online: https:\/\/www.cdc.gov\/vaccines\/vpd\/hpv\/hcp\/administration.html#:~:text=HPV%20vaccines%20are%20administered%20as,years%2C%20and%20for%20immunocompromised%20persons."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev. Med. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1542\/peds.2005-1142","article-title":"Risk Factors for Congenital Cytomegalovirus Infection in the Offspring of Young Women: Exposure to Young Children and Recent Onset of Sexual Activity","volume":"118","author":"Fowler","year":"2006","journal-title":"Pediatrics"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/infdis\/164.2.259","article-title":"Sexually transmitted diseases in mothers of neonates with congenital cytomegalovirus infection","volume":"164","author":"Fowler","year":"1991","journal-title":"J. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.idc.2015.05.009","article-title":"Strain Variation and Disease Severity in Congenital Cytomegalovirus Infection: In Search of a Viral Marker","volume":"29","year":"2015","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/clinids\/12.1.31","article-title":"Effectiveness and cost benefit of a proposed live cytomegalovirus vaccine in the prevention of congenital disease","volume":"12","author":"Porath","year":"1990","journal-title":"Rev. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1016\/j.vaccine.2012.04.011","article-title":"Cost-effectiveness of routine vaccination of adolescent females against cytomegalovirus","volume":"30","author":"Dempsey","year":"2012","journal-title":"Vaccine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.vaccine.2018.01.042","article-title":"Cost-effectiveness of vaccination against cytomegalovirus (CMV) in adolescent girls to prevent infections in pregnant women living in France","volume":"36","author":"Launay","year":"2018","journal-title":"Vaccine"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"N\u2019Diaye, D.S., Yazdanpanah, Y., Krivine, A., Andrieu, T., Rozenberg, F., Picone, O., Tsatasris, V., Goffinet, F., and Launay, O. (2014). Predictive Factors of Cytomegalovirus Seropositivity among Pregnant Women in Paris, France. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0089857"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/5\/523\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:03:42Z","timestamp":1760162622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/5\/523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":70,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["vaccines9050523"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9050523","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]}}}